FDA and Psychedelic Research
The late 1980s marked a pivotal shift in how the FDA approached drug evaluation, particularly for psychedelics. A new team emerged, advocating for a more science-driven approach, leading to the approval of groundbreaking studies on MDMA and DMT. This change not only allowed for the exploration of psychedelics in treating conditions like anxiety but also established a framework that recognized their medical potential, balancing risks with benefits.In this clip
From this podcast
The Joe Rogan Experience
Joe Rogan Experience #371 - Rick Doblin
Related Questions